Cardinal Capital Management Cut By $355,536 Its Novartis Adr (NVS) Stake; Atlantic Gold (CVE:AGB) Had 2 Analysts Last Week

June 20, 2017 - By wolcottdaily

Cardinal Capital Management decreased Novartis Adr (NVS) stake by 14.77% reported in 2016Q4 SEC filing. Cardinal Capital Management sold 4,938 shares as Novartis Adr (NVS)’s stock rose 4.17%. The Cardinal Capital Management holds 28,486 shares with $2.08M value, down from 33,424 last quarter. Novartis Adr now has $212.20B valuation. The stock increased 0.75% or $0.61 on June 19, reaching $81.44. About shares traded. Novartis AG (ADR) (NYSE:NVS) has risen 7.67% since June 20, 2016 and is uptrending. It has underperformed by 9.03% the S&P500.

Among 2 analysts covering Atlantic Gold Corp (CVE:AGB), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Atlantic Gold Corp had 3 analyst reports since August 12, 2015 according to SRatingsIntel. National Bank Canada initiated it with “Outperform” rating and $0.75 target in Wednesday, August 12 report. See Atlantic Gold Corp (CVE:AGB) latest ratings:

Among 14 analysts covering Novartis Ag (NYSE:NVS), 4 have Buy rating, 2 Sell and 8 Hold. Therefore 29% are positive. Novartis Ag had 22 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was initiated by Chardan Capital Markets with “Buy” on Tuesday, September 20. The stock of Novartis AG (ADR) (NYSE:NVS) has “Neutral” rating given on Friday, June 16 by J P Morgan Chase Co. The company was downgraded on Tuesday, April 12 by Morgan Stanley. On Wednesday, April 19 the stock rating was maintained by JP Morgan with “Neutral”. The firm has “Market Perform” rating by Leerink Swann given on Wednesday, March 23. The stock of Novartis AG (ADR) (NYSE:NVS) has “Neutral” rating given on Friday, April 1 by UBS. The firm has “Market Perform” rating given on Wednesday, April 5 by Cowen & Co. The company was downgraded on Wednesday, January 11 by Credit Suisse. The firm has “Buy” rating given on Thursday, November 10 by Argus Research. The company was initiated on Tuesday, April 5 by Argus Research.

Analysts await Novartis AG (ADR) (NYSE:NVS) to report earnings on July, 18. They expect $1.18 earnings per share, down 3.28% or $0.04 from last year’s $1.22 per share. NVS’s profit will be $3.07 billion for 17.25 P/E if the $1.18 EPS becomes a reality. After $1.13 actual earnings per share reported by Novartis AG (ADR) for the previous quarter, Wall Street now forecasts 4.42% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: